Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
Am J Med Sci. 2023 Dec;366(6):464-467. doi: 10.1016/j.amjms.2023.09.012. Epub 2023 Sep 15.
Eravacycline is the newest member of the broad-spectrum class of tetracycline antimicrobials. Pancreatitis has been previously associated with the tetracycline class of antibiotics, but, to our knowledge, we believe that this is the first reported case of eravacycline-induced pancreatitis. We describe a 46-year-old male who received eravacycline for treatment of a perirectal abscess. While the patient had slightly elevated lipase levels at baseline post-cardiopulmonary arrest, he developed abdominal pain and a further increase in lipase levels following 10 days of eravacycline, consistent with pancreatitis. Based on the Naranjo adverse drug reaction probability scale, eravacycline was the probable etiology of acute pancreatitis given improvement immediately after discontinuation. Clinicians should be aware of this potential adverse effect of eravacycline and should not initiate eravacycline in those with risk factors for acute pancreatic injury. However, acute pancreatitis should be suspected in all patients complaining of symptoms followed by immediate discontinuation of eravacycline.
依拉环素是广谱四环素类抗菌药物中的最新成员。胰腺炎先前与四环素类抗生素有关，但据我们所知，我们认为这是首例依拉环素引起的胰腺炎报告。我们描述了一位 46 岁男性，他因直肠周围脓肿接受依拉环素治疗。尽管患者在心肺骤停后基线时的脂肪酶水平略有升高，但在接受依拉环素治疗 10 天后出现腹痛和脂肪酶水平进一步升高，符合胰腺炎的表现。根据 Naranjo 药物不良反应概率量表，依拉环素是急性胰腺炎的可能病因，因为在停药后立即改善。临床医生应意识到依拉环素的这种潜在不良反应，并且不应在有急性胰腺损伤风险因素的患者中开始使用依拉环素。然而，所有出现症状的患者都应怀疑急性胰腺炎，并立即停用依拉环素。
